NCT06233708

Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant

Association Between Pre-operative Use of Non-selective Beta-blockers With the Risk of Hepatocellular Carcinoma Recurrence Following Liver Transplantation : a Retrospective Cohort Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 2,092 (actual)
• Sponsor: Asan Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this observational study is to investigate the effect of non-selective beta-blocker (NSBB) on the recurrence of hepatocellular carcinoma (HCC) following liver transplantation in patients who underwent liver transplantation (LT) for treating hepatocellular carcinoma. The main question\[s\] it aims to answer are: * Is the usage of non-selective beta-blocker associated with decreased recurrence of hepatocellular carcinoma following liver transplantation? * Is the usage of non-selective beta-blocker associated with all-cause mortality following liver transplantation? Researchers will compare the NSBB group, including patients who received non-selective beta-blocker therapy for at least 30 consecutive days within 3 months prior to liver transplantation more than 30 days prior, with the control group to to see if non-selective beta-blocker treatment is associated with decreased recurrence of hepatocellular carcinoma following liver transplantation.

Conditions

• Hepatocellular Carcinoma Recurrent
• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	Non-Selective Beta-Adrenoreceptor Agonists for Systemic Use	Non-selective blocker including Propranolol, Carvedilol PO was prescribed

Timeline

• Start date: 2008-01-01
• Primary completion: 2022-05-31
• Completion: 2022-05-31
• First posted: 2024-01-31
• Last updated: 2024-01-31